Ionis Pharmaceuticals reported positive pivotal Phase 3 results for olezarsen, significantly lowering triglyceride levels by up to 72% in patients with severe hypertriglyceridemia (sHTG) and reducing acute pancreatitis events by 85%. The drug demonstrated favorable safety and tolerability, with mild injection site reactions being the most common adverse events. These findings position olezarsen for an expanded label to target a broader population suffering from elevated triglycerides, promising a major commercial opportunity in a growing metabolic disease market.